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1. Introduction 
Cardiovascular diseases are the leading cause of mortality and morbidity in developed 
countries being atherosclerosis the major contributor. Atherosclerosis is a form of chronic 
inflammation characterized by the accumulation of lipids and fibrous elements in medium 
and large arteries (Libby, 2002). The retention of apoB-100 containing lipoproteins (mainly 
LDL and Lp(a)) in the subendothelial space and their subsequent oxidation is thought to be 
the leading event in the development of atherosclerotic lesions (Williams & Tabas, 1995). 
The degree of inflammation, proteolysis, calcification and neovascularization affects the 
stability of advanced lesions. Plaque rupture and thrombosis are the most important clinical 
complications in the pathogenesis of stroke, coronary arteries and peripheral vascular 
diseases (Lutgens et al., 2003). So, the identification of early biomarkers of plaque presence 
and susceptibility to ulceration could be of primary importance in preventing such a life-
threatening event. Disease aetiology is very complex and includes several important 
environmental and genetic risk factors such as hyperlipidemia, diabetes, and hypertension. 
In this regard elevated plasma levels of LDL cholesterol and low levels of HDL cholesterol 
have been long associated with the onset and development of atherosclerotic lesions. 
Although enormous efforts have been done to elucidate the molecular mechanisms 
underlying plaque formation and progression, they are not yet completely understood. In 
the last years, proteomic studies have been undertaken to both elucidate pathways of 
atherosclerotic degeneration and individuate new circulating markers to be utilized either as 
early diagnostic traits or as targets for new drug therapies. 
This chapter will provide an overview of latest advances in proteomic studies on 
atherosclerosis and some related diseases, with particular emphasis on vascular tissue 
proteomics and lipoproteomics.  
2. Application of proteomic technologies to the study of atherosclerosis 
Atherosclerosis is a very complex pathology in terms of cell types involved, inflammatory 
mechanisms and multifactorial aetiology. Many efforts have been done to shed light on the 
mechanisms underlying atherogenesis and to identify new circulating biomarkers which, 
along with traditional risk factors, will help in early diagnosis and prevention as well as in 
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monitoring the effects of pharmacological agents. To address these issues, proteomic studies 
have been focused on different matrices such as vascular cell/tissues, looking at both 
proteomes and secretomes, plasma/serum, urine, and purified plasma lipoprotein fractions 
(fig. 1).  
 
 
Fig. 1. Overview of the main targets of proteomic studies searching for both mechanisms of 
atherogenesis and biomarkers of atherosclerotic lesion presence and progression. Dotted 
lines represent almost unexplored paths. LCMs, laser-captured microdissections 
To date, several proteomic approaches, such as 1D-2D electrophoresis (1DE-2DE) followed 
by mass spectrometry (MS) analyses, western arrays, protein arrays, and gel-free MS based 
proteomics, have been applied in the search of vascular biomarkers of atherosclerosis. Often, 
classical biochemical methods, mainly western blotting (WB), ELISA, and 
immunohistochemistry (IH) have been used to validate the proteomic results. 
2.1 Vascular tissue proteomics 
Even though tissue analyses frequently provide useful data, there are major drawbacks in 
analysing human atherosclerotic specimens. Atherosclerotic plaques are quite complex in 
terms of vascular cells and extracellular components. In this respect, besides vascular 
smooth muscle cells (VSMCs) and endothelial cells (ECs), they are composed of 
inflammatory cells, filtered plasma proteins, new-formed extracellular matrix, cellular 
debris and end-products of lipid and protein oxidation. Another critical point in the in situ 
analysis of protein expression within atherosclerotic plaques is the choice of the appropriate 
control. It would be desirable to utilize control specimens from the same vascular district of 
the same patient, in order to minimize intrinsic tissue differences, and from surgical 
endarterectomy rather than from post-mortem material, to avoid the occurrence of 
proteolytic modifications prior to analysis. Also the availability of a significant number of 
human specimens could be limiting. Because of the complexity of advanced lesions (Stary, 
2000; Virmani et al., 2000) in terms of necrotic core dimension, fibrous cap thickness, 
inflammatory and proteolytic components, careful histochemical classification is needed. 
Moreover, results from different advanced lesion typologies are difficult to interpret because 
they could be either associated to the lesion development or merely a consequence of the 
advanced condition. In the latest years proteomic technologies have been applied to human 
diseased tissues to both characterize mechanisms of advanced atherosclerotic plaque 
development, mainly those responsible for its instability, and to identify markers useful in 
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diagnosis and patients treatment. Compared to tissue specimens of human origin, animal 
models, mainly rodents, have been utilized to study the mechanisms underlying the early 
stages of lesion formation. 
2.1.1 Studies on animal models 
Apolipoprotein E-deficient mouse is the most popular murine model in cardiovascular 
research and has revealed important insights into mechanisms affecting atherogenesis. Mayr 
et al. analysed aortic lesions from apolipoprotein E-/- and wild type mice classified as light, 
medium, and severe according to lesion-covered areas on the aortic surface (Mayr et al., 
2005). As expected, authors found an increase of inflammatory cells, a decrease of VSMCs, 
and an accumulation of serum proteins associated to an impaired endothelial barrier 
function with lesion progression. Interestingly, immunoglobulins, that were barely 
detectable in apolipoprotein E+/+ mice, accumulated even in aortas of young apolipoprotein 
E-/- mice. The authors identified 79 differentially expressed spots. Moreover, they suggested 
an increase in oxidative stress with lesion progression evaluating the ratio between the 
oxidized and the reduced forms of peroxiredoxin, the former resulting in a charge shift 
toward a more acidic isoelectric point. Overall, they found a linear relationship between the 
degree of peroxiredoxin-Cys oxidation and the extent of lesion formation in aortas of 
apolipoprotein E-deficient mice. Almofti et al. applied 2DE coupled to matrix-assisted laser 
desorption/ionization time of flight (MALDI TOF) MS analysis to a rat model of 
atherosclerosis. They induced atherosclerosis by a single dose of vitamin D3 associated with 
a high fat diet and identified 46 proteins differently expressed in diseased tissues. Among 
them, 18 proteins, including a group of oxidization-related enzymes, were found to be up-
regulated, while 28 proteins were found down-regulated (Almofti et al., 2006). Vascular 
endothelium plays important physiological roles in vascular homeostasis, coagulation, 
inflammation, as well as tissue growth and repair. Impairment of the endothelial function is 
an early event in atherosclerotic lesion formation leading to overexpression of adhesion 
molecules as well as secretion of pro-inflammatory and chemotactic cytokines. An affinity-
based proteomic approach was used by Wu et al. (Wu et al., 2007) to identify vascular 
endothelial surface proteins differentially expressed in aortic tissues of apolipoprotein E 
deficient mice. After in situ perfusion of vascular bed with a solution containing a biotin-
derivative, biotinylated endothelial proteins were extracted, purified by affinity enrichment 
with streptavidin-agarose beads, and resolved by SDS-PAGE. The whole gel lanes were cut 
into slices that were subjected to tryptic digestion for nano liquid chromatography (LC) 
MS/MS analysis. In this way, 454 proteins, mainly extracellular or associated to cell 
membrane, were identified. Among them, there were cell adhesion molecules, accounting 
for the largest category, followed by proteins involved in signal transduction and transport. 
Interestingly, proteins associated with immune and inflammatory responses were more than 
doubled in atherosclerotic aorta (13%) in comparison to normal aorta (6%). On the other 
hand, proteins involved in lipid metabolism were decreased by 34% in atherosclerotic aorta. 
A rat model has been recently used for a proteomic study on the effects of blood shear stress 
on atherogenesis (Qi et al., 2008). It is well known that blood shear stress affects endothelial 
cell shape and orientation, as well as vascular wall permeability. Indeed, regions of arterial 
branching or curvature, where blood flow is not uniform, are preferential sites for lesion 
formation. By comparing homogenates of aortas kept under two levels of shear stress in a 
perfusion culture system for 24 hours, Qi et al. detected a reduced expression of protein 
Rho-GDP dissociation inhibitor alpha (Rho-GDIǂ) in low shear stress conditions and 
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demonstrated, by siRNA technology, that this reduction enhances VSMC migration and 
apoptosis. 
2.1.2 Studies on human tissues 
As from 2003, 14 researches on human atherosclerotic plaque proteomics have been 
published; the diseased tissues used as matrices were coronary arteries (2/14), carotid 
arteries (11/14), and aortas (1/14).  
Most of them were conducted by using two-dimensional electrophoresis coupled to mass 
spectrometry as analytical method (10/14). The sample source, the methodology applied, 
and the most relevant findings of these studies are summarized in table 1. 
In 2003, You et al., by analysing 10 diseased (coronary artery disease, CAD) and 7 normal 
autoptic coronary arteries, reported about 2 fold increase of the ferritin light chain in the 
pathological specimens (You et al., 2003). Quantitative analysis by real-time PCR showed a 
decrease in ferritin light chain mRNA expression in diseased tissues suggesting that the 
increased expression of ferritin light chain in CAD coronary arteries may be related to 
increased protein stability. This result highlights the importance of protein expression 
analysis in studying disease-associated gene expression. Donners et al. analysed 5 stable 
plaques and 6 lesions with a thrombus from patients undergoing carotid endarterectomy, 
classified according to Virmani et al. (Donners et al., 2005). By 2DE analysis, they identified 
vinexin-ǃ and ǂ1-antitrypsin as differentially expressed. However, neither 
immunohistochemistry nor western blotting confirmed vinexin-ǃ differential expression 
underlining the importance of validating proteomic results by other biochemical methods. 
Conversely, western blotting of 2D gels revealed, in lesions with a thrombus, the expression 
of six isoforms of the acute phase protein ǂ1-antitrypsin, one of which was uniquely 
expressed in thrombus-containing plaques. Sung et al. analysed non-diseased and 
atherosclerotic specimens from 7 patients undergoing aorta bypass surgery. They identified 
a panel of 27 proteins differentially expressed in the atherosclerotic aorta involved in a 
number of biological processes, including calcium-mediated processes, migration of VSMCs, 
matrix metalloproteinase activation and regulation of pro-inflammatory cytokines (Sung et 
al., 2006). A different approach was adopted by Martin-Ventura et al. who analysed the 
protein secretion profiles obtained from 35 cultured atherosclerotic plaques (10 femoral, 25 
carotids) and 36 control arteries (24 mammary, 12 radial) in the search of new biological 
markers potentially released by the arterial wall into the plasma (Duran et al., 2003; Martin-
Ventura et al., 2004). In particular, they isolated and analysed the secretomes from non-
complicated and ruptured/thrombosed areas of the same cultured carotid plaque so 
avoiding the variability of the control specimens. They showed that, compared to control 
arteries, heat shock protein 27 (HSP27) secretion into the culture medium was significantly 
lower in atherosclerotic plaques and barely detectable in complicated plaque supernatants, 
as confirmed by WB analysis. They also evidenced a 20-fold reduction in HSP27 levels in the 
plasma of patients with carotid stenosis respect to healthy controls so identifying HSP27 as a 
possible marker of atherosclerosis. The same research group evaluated the effects of 
incubation with atorvastatin, a 3-hydroxy-3-methylglutaryl CoenzymeA reductase inhibitor, 
on the secretomes of cultured atherosclerotic plaques (Durán et al., 2007). They identified 24 
proteins that were increased and 20 proteins that were decreased in atherosclerotic plaque 
supernatants compared to controls. Interestingly, the presence of atorvastatin in culture 
medium reverted secretion of 66% proteins to control values. In this report, authors 
identified cathepsin D as a potential target for therapeutical treatment of atherosclerosis.  
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Human tissues (Methods) Results Known functions Ref. 
10 coronary arteries from CAD 
patients vs 7 normal autoptic coronary 
arteries 
 
(2DE of homogenates, LC-MS/MS, 
WB, rt-PCR) 
↑ ferritin light chain 
↓ ferritin light chain 
mRNA 
modulation of 
oxidation 
You et al., 2003 
6 carotid plaques containing a 
thrombus vs 5 advanced stable lesions
 
(2DE of homogenates, MALDI-
TOF/TOF MS, LC-MS/MS, WB, IH) 
↑ ǂ1-antitrypsin acute-phase protein Donners et al., 
2005 
7 atherosclerotic aortic specimens vs 
biopsies of the normal tissue from the 
same patients 
 
(2DE of homogenates, MALDI-TOF 
MS, WB) 
↑ 39 proteins 
(27 identified) 
signal transduction 
angiogenesis 
MMP activation 
regulation of pro-
inflammatory 
cytokines 
Sung et al., 
2006 
35 atherosclerotic endarterectomies (10 
femoral, 25 carotids) vs 36 control 
endarteries (24 mammary, 12 radial) 
 
(2DE of secretomes, MALDI-TOF MS, 
LC-MS/MS and IMAC combined with 
MALDI Q-TOF MS/MS, WB, ELISA, 
IH) 
↓↓ HSP27 secretion 
↓↓ HSP27 plasma levels
anti-inflammatory 
down-regulation of the 
apoptotic signaling 
pathway 
Duran et al., 
2003; Martin-
Ventura et al., 
2004 
21 stenosing complicated carotid 
regions with/without atorvastatin 
treatement vs fibrous regions (ex vivo)
 
(2DE of secretomes, MALDI-TOF MS, 
LC MS/MS, WB) 
↑ 24 proteins 
↓ 20 proteins 
Treatment reverts the 
differential protein 
secretion 
modulation of 
oxidation and 
inflammation 
structural 
signaling pathway 
cholesterol metabolism
Durán et al., 
2007 
29 unstable carotid plaques vs 19 
stable carotid plaques 
 
(2DE of extracts, MALDI-TOF MS, 
WB) 
↑ ferritin light subunit 
↑ superoxide dismutase 
2 
↑ fibrinogen fragment D
↓ superoxide dismutase 
3 
↓ glutathione S-
transferase 
↓ Rho GDP-dissociation 
inhibitor 1 
↓ annexin A10 
↓ HSP 20 
↓ HSP 27 
modulation of 
inflammation and 
oxidative stress 
Lepedda et al., 
2009 
10 complicated segments in the 
internal carotid artery (ICA) vs 10  
stable segments in the common carotid 
artery (CCA) 
 
(2-D DIGE of homogenates, LC-
MS/MS, IH) 
↑ 6 proteins 
↓ 11 proteins 
2 proteins with isoform 
dependent distributions
signal transduction 
transport 
cell growth 
metabolism 
Olson et al., 
2010 
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Human tissues (Methods) Results Known functions Ref. 
10 carotid plaques vs reference 
synthetic gel 
 
(2DE of homogenates,  LC-MS/MS) 
Identification of proteins 
exclusive to plaque 
Terzuoli et al., 
2007; Porcelli 
et al., 2010) 
IMAC, immobilized metal affinity chromatography. ↑, increase. ↓, decrease. 
Table 1. 2DE coupled to MS studies on the human atherosclerotic plaque.  
Since carotid plaque rupture and thrombosis are the most important clinical complications 
in the pathogenesis of cerebro-vascular diseases, many efforts have been done to elucidate 
mechanisms underlying plaque vulnerability and to identify reliable specific markers of 
plaques prone to rupture. In a previous study we provided evidence for a wide 
fragmentation of some apolipoproteins and arterial proteoglycans and for a pro-
inflammatory microenvironment in unstable and much less in stable endarterectomy carotid 
plaques (Formato et al., 2004). Recently, we evaluated differential protein expression in a 
considerable number (n=48) of plaques obtained from carotid endarterectomy classified by 
immunohistochemistry in stable and unstable (Lepedda et al., 2009). Our study was carried 
out on the premise that plaque stability/instability is associated with distinct patterns of 
protein expression. We analysed extracts from finely minced tissues in order to allow 
enrichment in both topically expressed and filtered/retained proteins. A total of 57 distinct 
spots corresponding to 33 different proteins were identified in both stable and unstable 
plaques by peptide mass fingerprinting (PMF) analysis, most of which were of plasma 
origin (about 70%). This suggested the existence of an impaired endothelial barrier function 
independent from plaque typology. Compared to stable plaques, unstable ones showed 
reduced abundance of protective enzymes superoxide dismutase 3 and glutathione S-
transferase, small HSP 27 and 20, annexin A10, and Rho GDP-dissociation inhibitor and a 
higher abundance of ferritin light subunit, superoxide dismutase 2 and fibrinogen fragment 
D. These proteins are described to play a role in either oxidative or inflammatory processes 
and in the formation and progression of the atherosclerotic plaque. Our proteomic 
approach, trying to differentiate unstable from stable human carotid plaques, identified, in 
the former, a panel of proteins with pro-oxidant and pro-inflammatory potentials according 
to our current understanding of the molecular basis of the atherosclerotic process. 
To overcome inter-individual variations in protein expression, Olson et al. applied 2-D 
differential in gel electrophoresis (2D DIGE) in combination with MS/MS to compare 
protein distribution in 10 complicated segments located in the internal carotid artery (ICA) 
with that in 10 more stable segments in the common carotid artery (CCA) from the same 
patient (Olson et al., 2010). In this way, they identified 19 proteins with differential 
distribution between ICA and CCA segments. To overcome the problem of plaque 
heterogeneity, Terzuoli et al. proposed a method for selecting proteins exclusive to plaque 
by constructing a reference synthetic gel (Terzuoli et al., 2007; Porcelli et al., 2010). This gel, 
obtained by averaging the positions, shapes and optical densities of spots in 2DE maps from 
10 carotid plaque samples was compared with an equivalent synthetic gel constructed using 
10 plasma samples from the same carotid surgery patients. The comparison allowed 
discriminating between plasma and plaque proteins, the latter being potential markers of 
plaque vulnerability. 
Some alternative proteomic approaches have been applied to date in the search of new 
biomarkers of the atherosclerotic process (table 2). 
www.intechopen.com
Overview of Current Proteomic Approaches  
for Discovery of Vascular Biomarkers of Atherosclerosis 
 
9 
Human tissues 
(Methods) 
Results Known 
functions 
Ref. 
12 carotid endarterectomy 
specimens vs 7 non-
atherosclerotic mammary arteries
 
(Western array (823 Abs), WB, rt-
PCR, IH) 
↓↓ apoptosis-linked 
gene 2 
 
↑↑ Thrombospondin-2, 
Mn superoxide 
dismutase, 
apolipoprotein B-100, 
protein-tyrosine 
phosphatase 1C, 
apolipoprotein E 
 
↓↓ glycogen synthase 
kinase-3ǃ 
mediator of 
apoptosis 
Martinet et 
al., 2003 
4 pooled unstable carotid plaques
vs 4 pooled stable carotid plaques
 
(protein microarray analysis of 
the expression of 512 proteins) 
↑ 21 proteins
↓ 3 proteins 
modulation of 
inflammatory, 
angiogenic, 
proliferative, and 
apoptotic 
pathways 
Slevin et al., 
2006 
Histological sections from 35
coronary vessels in paraffin or 
frozen blocks 
 
(direct tissue proteomics 
AQUA methodology) 
806
unique proteins 
identified with high 
confidence 
Bagnato et 
al., 2007 
Carotid plaques from 80 patients 
that had a secondary 
cardiovascular event vs 80 sex 
and age matched event-free 
patients (during a 3-year follow-
up) 
 
(LC MS/MS) 
Strong positive 
association between 
osteopontin and the 
occurrence of new 
vascular complications
de Kleijn et 
al., 2010 
↑, increase. ↓, decrease. 
Table 2. Alternative approaches in proteomics of the atherosclerotic plaque.  
High-throughput western blot analysis, also called western array, was used to screen cell 
lysates from 12 carotid endarterectomy specimens and 7 non-atherosclerotic mammary 
arteries, obtained during bypass surgery, with 823 monoclonal antibodies mainly directed 
against signal-transducing proteins (Martinet et al., 2003). Western arrays showed a highly 
reproducible pattern of protein expression but also a high rate of false-positive signals 
(differential protein expression of only 7 of the 15 proteins detected by using this method 
was confirmed by standard immunoblot assay). A strong down regulation of apoptosis-
linked gene 2 (ALG-2) was found, suggesting a novel mechanism inhibiting cell death in 
human advanced atherosclerotic plaques.  
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By using microarray technology, Slevin et al. compared the expression of 512 proteins 
associated with inflammatory, pro/anti-apoptotic, and angiogenesis pathways between 4 
pooled fibrous stable carotid plaques and 4 pooled ulcerated, hemorrhagic unstable plaques 
(Slevin et al., 2006). In spite of the high sensitivity of protein microarrays, allowing detecting 
nanogram quantities, errors can occur because of weakly reacting or nonspecific antibodies, 
degraded proteins, and/or the efficiency of sample fluorescent labelling. However, western 
blotting analyses confirmed differential expression between stable and unstable plaque 
pools for all 11 proteins selected suggesting a high level of specificity of the array antibodies 
and the usefulness of this proteomic approach in the study of plaque pathogenesis. 
Atherosclerotic tissue could also be laser-microdissected, which would allow one to 
compare different areas of the plaque such as necrotic core and shoulders/fibrous cap, 
providing valuable spatial information. Bagnato et al. applied the direct tissue proteomic 
(DTP) approach to paraffin or frozen blocks from 35 coronary atherosclerotic lesions 
classified by histopathological examination in early, intermediate, and advanced (Bagnato et 
al., 2007). In particular, different plaque regions were laser-microdissected (LCMs) from 
both paraffin and frozen sections and subjected to tryptic digestion followed by LC MS/MS 
to obtain area-specific proteomic information. Frozen sections were also homogenized and 
proteins resolved by SDS PAGE and analysed by LC MS/MS. Moreover, they used AQUA 
(absolute quantitation) methodology to quantify Stromal Cell-derived Factor 1 ǂ (SDF1-ǂ) 
and growth factors not detected by the above mentioned methods. These multiple 
approaches allowed them to identify 806 unique proteins with high confidence so obtaining 
a large scale protein profile of human atherosclerotic coronary arteries.  
Recently, de Kleijn et al. analysed carotid endarterectomy specimens from 80 patients that had 
a secondary cardiovascular event in the 3-year follow-up and 80 sex and age matched event-
free patients, by two HPLC fractionations coupled to MS (de Kleijn et al., 2010). They identified 
osteopontin as potential biomarker and validated data by assaying its level in a group of 574 
patients that underwent carotid endarterectomy and a group of 151 patients that underwent 
femoral endarterectomy included in the follow-up. Osteopontin resulted highly predictive for 
secondary manifestations of cardiovascular events in other vascular territories.  
Atherosclerosis is characterized by high oxidative and proteolytic activities. This process 
may lead to a pathological remodelling of aorta characterized by dilatation that can evolve 
toward vessel wall rupture (aortic aneurysm). Recently, Dejouvencel et al. focused their 
attention on intraluminal mural thrombus that develops in human abdominal aortic 
aneurysm (Dejouvencel et al., 2010). In particular, they analysed the protein released from 
three different aortic layers of the intramural thrombus (luminal, intermediate and 
abluminal), after 24 hours incubation on RPMI medium, by surface-enhanced laser 
desorption/ionization (SELDI) TOF MS profiling. They identified a peptide that was largely 
abundant in newly formed luminal layer respect to the other areas as hemorphin 7, a 
proteolytic fragment of the hemoglobin. The levels of this peptide were confirmed (by 
ELISA) to be higher in sera of abdominal aortic aneurysm patients respect to controls, and 
positively correlated with the volume of the thrombus. This peptide has been suggested as a 
potential marker of pathological vascular remodelling. 
2.2 Vascular cell proteomics 
As mentioned above, the study of atherosclerotic specimens are complicated by both the 
heterogeneous cellular composition and the inflammatory/proteolytic environment. In this 
respect, cell culture systems could represent a useful tool to partially overcome drawbacks 
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of tissue analyses, allowing researchers to study single aspects of the atherosclerotic process 
in very controlled conditions. In the last years, studies on proteome (the intracellular 
proteins) and secretome (the proteins released into the cell culture medium) by 2DE and MS 
of ECs (Bruneel et al., 2003; Chen et al., 2007; Tunica et al., 2009), VSMCs (McGregor et al., 
2001; Dupont et al., 2005; Lee et al., 2006), and monocytes/macrophages (Dupont et al., 2004; 
Fach et al., 2004; Slomianny et al., 2006; Zhang et al., 2007; Zhao et al., 2009) have been 
performed. Moreover, in the attempt to help in elucidating the mechanisms of 
atherogenesis, several proteomic studies have been carried out on vascular cells cultured in 
different experimental conditions (table 3). The most applied proteomic methodologies were 
1DE-2DE coupled to MS analyses. Very few studies applied gel free proteomic approaches 
such as LC MS/MS (Fach et al., 2004; X.L. Wang et al., 2007; Zhao et al., 2009; Tunica et al., 
2009; Zimman et al., 2010) and microarrays (Sukhanov et al., 2005). 
2.3 Plasma/serum proteomics 
Plasma is one of the most useful matrices to investigate for identifying new biomarkers. It 
carries resident proteins that represent the majority of plasma proteins, together with 
proteins released from vascular cells and other tissues. In this respect, variations in plasma 
proteome could reflect directly or indirectly a cardiovascular disease or other pathological 
conditions. Moreover, monitoring plasma proteome could be successful in patients follow 
up and in relation to drug therapies. Besides plasma, also serum is widely investigated, 
although its proteome is known to be drastically affected by blood coagulation. Plasma 
proteomic studies are challenging due to both the high dynamic range of protein 
concentrations and the number of low expressed proteins. Plasma is composed for up to 
99% by 21 most abundant proteins and for the remaining 1% by about 50,000 low expressed 
protein variants, representing the so called “deep proteome” (Righetti et al., 2005). Plasma 
protein levels range from 40-50 mg/ml for albumin to less than 10 ng/ml for interleukins, 
chatepsins and peptide hormones. Therefore, differential proteomics of unfractionated 
plasma provides only limited information. In this regard, several pre-analytical depletion 
systems that imply affinity/immunoaffinity steps for simultaneous removal of the most 
represented plasma proteins have been set up. However, due to non-specific binding, many 
other proteins could be depleted. Besides depletion systems, also protein enrichment 
technology has been developed. This relies on solid-phase combinatorial ligand libraries, 
made of hexapeptides, to reduce the high dynamic range of protein concentration 
preventing the co-depletion of low-abundance proteins (Boschetti et al., 2007). Since 
variations in plasma protein expression can provide useful information on both 
physiological and pathological conditions of the different tissues in the body, many efforts 
have been made in characterizing the entire human plasma proteome. In this regard, during 
2003-2005, 55 laboratories worldwide participating to the Human Plasma Proteome Project 
(HPPP) analysed reference specimens by using emerging technologies in the field of 
proteomics, and generated integrated databases for proteins detectable and identifiable in 
human serum and plasma (http://www.hupo.org/research/hppp/). They confidently 
identified 3020 proteins with a minimum of two high-scoring MS/MS spectra that have 
been searched for relevance to cardiovascular function and disease using PubMed search 
engine and specific keywords. On the basis of the current knowledge, the study 
individuated a subset of 345 proteins showing cardiovascular-related functions (markers of 
inflammation and/or cardiovascular disease, proteins implicated in coagulation, signalling, 
growth, differentiation, and vascular remodelling) (Berhane et al., 2005).  
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Experimental 
conditions 
Endothelial cells Smooth muscle 
cells 
Monocytes/macrophages 
Senescence Kamino et al., 
2003 
  
Shear stress X.L. Wang et al., 
2007; Huang et al., 
2009 
McGregor et al., 
2004 
 
Pro-inflammatory 
conditions 
Lomnytska et al., 
2004; Pawlowska 
et al., 2005; 
González-Cabrero 
et al., 2007 
Boccardi et al., 
2007 
 
Oxidized/aggregated 
LDL 
Chen et al., 2007 Sukhanov & 
Delafontaine, 
2005; Padró et al., 
2008 
Fach et al., 2004; Conway & 
Kinter, 2005; Dupont et al., 
2004; Kang et al., 2009; 
Burillo et al., 2009; Y.L. Yu 
et al., 2003a; Y.L.Yu et al., 
2003b 
Antioxidant/oxidant Ha et al., 2005; 
Zimman et al., 
2010 
Jang et al., 2004; 
Lee et al., 2006 
 
Cholesterol loading T. Wang et al., 
2006 
  
HSP27 over-expression Trott et al., 2009   
Drug treatment M. Yu et al., 2004; 
Bieler et al., 2009; 
Millioni et al., 
2010 
Won et al., 2011 Barderas et al., 2009 
PKCδ-/-   Mayr et al., 2004  
Hyperinsulinemia  Y. Wang et al., 
2010 
 
Lipopolysaccharide or 
phorbol myristate 
  Gadgil et al., 2003; 
Sintiprungrat et al., 2010 
ACS vs CAD   Barderas et al., 2007 
ACS, acute coronary syndrome; CAD, coronary artery disease 
Table 3. Literature overview of experimental conditions adopted in proteomic studies on 
ECs, VSMCs and monocytes/macrophages. 
In the latest years, proteomics has been applied to plasma/serum to identify early 
diagnostic markers in relation to several cerebro-cardiovascular pathologies such as stroke 
(Allard et al., 2004; Kiga et al., 2008; Brea et al., 2009; Prentice et al., 2010), acute coronary 
syndrome (Mateos-Cáceres et al., 2004; Dardé et al., 2010), angiographic coronary disease 
(Donahue et al., 2006), acute myocardial infarction (AMI) (Distelmaier et al., 2009), coronary 
heart disease (CHD) (Prentice et al., 2010), coronary artery bypass grafting (CABG) (Banfi et 
al., 2010), aortic atherosclerotic plaque (Tabibiazar et al., 2006), and peripheral arterial 
disease (Wilson et al., 2007). Moreover, differential proteomic analysis has been addressed to 
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elucidate effects on plasma proteome of different pharmacological treatments (Alonso-
Orgaz et al., 2006; López-Farré et al., 2007). In this regard, the most applied proteomic 
methodologies were gel electrophoresis coupled to mass spectrometry analyses followed by 
gel free proteomic approaches such as LC MS/MS (Donahue et al., 2006; Wilson et al., 2007; 
Prentice et al., 2010) and microarrays (Tabibiazar et al., 2006). Almost all of these analytical 
approaches were preceded by one or more fractionation steps, mainly immunoaffinity 
depletion of the most abundant plasma protein species and ion exchange chromatography, 
to reduce the high complexity of plasma samples in terms of both number and dynamic 
range of protein species. Since many genetic and environmental factors affect atherosclerosis 
aetiology, one of the main drawbacks in differential analysis is the choice of a proper control 
group. In particular, results could be affected by coexisting pathological conditions such as 
dyslipidemia, hypertension and diabetes. 
2.4 Urine proteomics 
Urine is an easily accessible body fluid, stable against proteolytic degradation even after 
long storage times, and it represents a rich source of information. Urine protein and peptide 
composition results from glomerular filtration and proximal tubular absorption of 
circulating proteins (30%) and from the kidney and the urinary tract (70%) (Decramer et al., 
2008). Urine proteomics is emerging as a powerful tool for identifying new biomarkers 
useful in diagnosis and monitoring of several human diseases. However, the urinary 
proteome analysis is not a simple task because the urine shows low protein concentration 
and high levels of salts or other interfering compounds. Moreover, urinary proteome is 
highly influenced by both inter-individual and intra-individual variability, the latter due to 
physical training, diet, drugs, caffeine consumption, etc. One of the priorities in this field 
during the coming years is to optimize sample preparation methods for urine proteomics 
(Thongboonkerd V., 2007). 2DE coupled with MS has represented for years the technique of 
choice for the analysis of urine proteins. Recently, Candiano et al. resolved 1118 spots in 
normal urine samples, 275 of which were characterized as isoforms of 82 proteins, 30 (108 
spots) corresponding to typical plasma components (Candiano et al., 2010). However, the 
identity of most of the proteins found in normal urine by 2DE remains to be determined, the 
majority being low-molecular weight proteins (<30 kDa). By means of 1DE and HPLC as 
fractionation methods, and nano LC MS/MS and MS3 as analytical methods, Adachi et al. 
identified 8041 peptides corresponding to 1543 proteins, probably representing the most 
advanced proteomic approach to urine characterization (Adachi et al., 2006). 
The study of urinary proteome in relation to atherosclerosis is in its infancy but, in the last 
years, many efforts have been done. In particular, multiple urinary biomarkers of CAD have 
been described (Zimmerli et al., 2008; von Zur Muhlen et al., 2009; Delles et al., 2010) by 
means of capillary electrophoresis coupled online to micro time-of-flight mass spectrometry. 
A pattern of 238 CAD-specific polypeptides (49 of which have been sequenced) that 
identifies patients with high sensitivity and specificity has been defined. 
2.5 Lipoproteomics 
In 1995 Williams and Tabas published the “response-to-retention” hypothesis. According to 
this theory, early events in atherogenesis are related to a selective retention of LDL in the 
sub-endothelial space by means of specific interactions with some extracellular matrix 
components (Williams & Tabas, 1995). The molecular mechanisms underlying these 
processes are not completely understood, but knowledge of lipoprotein structure, 
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apolipoprotein composition and their post-translational modifications could help in this 
respect. There are several types of lipoproteins differing for chemical compositions, physical 
properties and metabolic functions. They may be classified according to their densities in 
chylomicrons (d< 0.95 g/ml), very low density lipoproteins (VLDL, d< 1.006 g/ml), low 
density lipoproteins (LDL, 1.019<d<1.063 g/ml), high density lipoproteins (HDL, 
1.063<d<1.21 g/ml) (Vance & Vance, 2008). A further class of lipoprotein particles is known 
as lipoprotein(a) (Lp(a)). Lp(a) is a LDL-like particle that carries, linked to apoB100 by a 
single disulfide bond, an heavily glycosylated multi-kringle protein named 
apolipoprotein(a). The physiological role of Lp(a) is unknown, although it is considered a 
risk factor for cardiovascular disease. Lipoproteins have attracted a great deal of interest 
because of their implication in the development of cardiovascular diseases, such as 
atherosclerosis. Although it is well known that high LDL-cholesterol and low HDL-
cholesterol are positively correlated with the risk for the development of cardiovascular 
disease, clinical studies suggest that levels of apo B-100 and apo A-I may be better predictors 
(Walldius et al., 2001). Since the protein component of these particles is largely responsible 
for carrying out their various functions, detailed information about the apolipoprotein 
composition and structure may contribute to reveal their role in atherogenesis and to 
develop new therapeutic strategies for the treatment of lipoprotein-associated disorders. 
Applying proteomics to the study of lipoproteins seems to contribute significantly to the 
achievement of this goal. Indeed, recent proteomic studies have revealed that lipoproteins 
carry an array of proteins previously unsuspected. Among proteomic approaches, 2DE was 
applied to the study of lipoprotein particles for the first time in the 1970s (Emes et al., 1976) 
and allowed to reveal several protein isoforms (Zannis, 1986). With the improvement of 2DE 
technologies, due to the advent of immobilized pH gradient strips, in the last ten years 
several studies have been done in the attempt to elucidate the apolipoprotein cargo of the 
different lipoprotein species. In this respect, besides 2DE, several gel-free mass spectrometry 
based proteomics have been applied. So far, 31 proteomic studies on VLDL, LDL and HDL 
have been published, while no proteomic studies on chylomicrons or Lp(a) are present in 
literature. Among them, only 9 focused on lipoproteomics in relation to atherosclerosis in 
humans (table 4). 
Before overviewing lipoproteomic studies, it is worth mentioning that the method used to 
isolate lipoproteins significantly affects the protein content of the resulting particles. 
Traditional methods, established in the 1950s (Havel et al., 1955), imply ultracentrifugation in 
high-salt media containing KBr or NaBr. Several lipoproteomic studies have been published 
using these procedures of lipoprotein isolation (Banfi et al., 2009; Davidson et al., 2009; Green 
et al., 2008; Heller et al., 2005, 2007; Hortin et al., 2006; Karlsson et al., 2005a, 2005b; 
Khovidhunkit et al., 2004; Mancone et al., 2007; Mazur et al., 2010; Rezaee et al., 2006; Vaisar et 
al., 2007, 2010; Alwaili et al, 2011). However, the high ionic strength and the high centrifugal 
field forces might cause either the dissociation of proteins or their exchange between different 
lipoprotein classes, altering the pattern of associated exchangeable apolipoproteins. Indeed, 
some of these studies reported a loss of proteins after a second step of ultracentrifugation 
(Banfi et al., 2009; Davidson et al., 2009; Mancone et al., 2007). Some others employed two 
ultracentrifuge procedures, using both salts and other compounds, such as sucrose and 
iodixanol (Bondarenko et al., 1999; Sun et al., 2010), reporting comparable results. By the way, 
Stahlman et al. reported that deuterium oxide (D2O) is to be preferred over salts at least for 
LDL and HDL, since for VLDL isolation, the ionic strength of the solution is not so  
relevant (Ståhlman et al., 2008). Alternatively, lipoprotein can be isolated by means of  
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Subjects analysed Purification methods 
Proteomic methods 
Results Ref. 
VLDL    
1 hyperlipidemic subject 
vs 3 healthy subjects 
ultracentrifugation in sucrose 
or in NaBr density gradient 
 
MALDI-TOF and ESI-TOF MS
↑ apo C-III Bondarenko et al., 
1999 
LDL  
10 subjects with 
metabolic syndrome and 
subclinical carotid 
atherosclerosis vs 10 
healthy controls 
 
21 patients with type 2 
diabetes and 
atherosclerosis vs 23 
healthy controls. 
ultracentrifugation in D2O 
density gradient (small dense 
LDL) 
 
SELDI-TOF MS 1DE MALDI-
TOF/TOF 
WB 
Proteins 
differentially 
expressed in small 
dense LDL: 
↑ apo C-III (3 
isoforms), 
↓ apo C-I 
(2isoforms), 
↓ apo A-I, 
↓ apo E 
Davidsson et al., 
2005 
HDL  
20 control subjects for 
total HDL analysis 
 
7 CAD subjects vs 6 
control subjects for HDL3 
analysis 
ultracentrifugation or affinity 
chromatography 
 
LC-ESI MS/MS 
48 proteins 
identified in total 
HDL 
HDL3 analysis: 
↑apo C-IV, 
↑PON1, 
↑complement C3, 
↑apo A-IV, 
↑apo E 
Vaisar et al., 2007 
6 CAD subjects treated 
with niacin  and 
atorvastatin for 12 
months vs 6 non treated 
CAD subjects 
sequential salt 
ultracentrifugation (HDL3) 
 
LC–Fourier transform Ion 
Cyclotron Resonance –MS 
↑PLTP,
↑apo F, 
↑apo J, 
↓apo E 
Green et al., 2008 
18 men with established 
CAD vs 20 apparently 
healthy men 
sequential salt 
ultracentrifugation (HDL2) 
 
MALDI-TOF MS and pattern 
recognition analysis 
LC-MALDI-TOF/TOF 
↑apo C-III,
↓apo C-I 
↑apo A-I peptides 
containing 
oxidized 
methionine 
Vaisar et al., 2010 
7 hypercholesterolemic 
subjects vs 9 
normolipidemic subjects
ultracentrifugation in salt 
density gradient 
 
Shotgun LC-ESI MS/MS 
↓apo A-I,
↑apo C-I, 
↑apo C-III, 
↑apo E 
Heller et al., 2007 
3 subjects having low 
HDL-cholesterol vs 3 
subjects having high 
HDL-cholesterol 
ultracentrifugation in salt 
density gradient 
(HDL3) 
 
Top-down Differential Mass 
Spectrometry 
380 peaks 
↑ two forms of apo 
C-III 
Mazur et al., 2010 
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Subjects analysed Purification methods 
Proteomic methods 
Results Ref. 
10 subjects having low 
HDL-cholesterol vs 10 
subjects having high 
HDL cholesterol 
challenged with 
lipopolysaccharide (24 
hours follow up) 
apo A-I immunocapturing 
 
SELDI-TOF MS 
profound changes 
in 21 markers in 
both groups 
Levels et al., 2011 
10 ACS subjects vs 
10 stable CAD vs 
10 healthy control 
subjects 
KBr sequential 
ultracentrifugation 
 
1D LC-MS/MS 
WB 
ELISA 
67 proteins 
identified 
 
↓ apo A-IV 
↑SAA 
↑complement C3 
Alwaili et al., 2011 
↑, increase. ↓, decrease. 
Table 4. Overview of the lipoproteomic studies related to atherosclerosis in humans 
reviewed in the chapter. 
immunopurification methods that rely on antibodies specific for the dominant protein of 
each class (Levels et al., 2007, 2011; Ogorzalek Loo et al., 2004; Rashid et al., 2002; Rezaee et 
al., 2006). Although this procedure does not lead to loss of weakly associated protein, it 
tends to nonspecifically co-purify associated proteins as serum contaminants and other 
lipoprotein fractions having the same antibody target (e.g. apolipoprotein A-I is the main 
HDL apolipoprotein but it is also present in both VLDL and LDL fractions). Other 
lipoprotein isolation methods that have been applied in lipoproteomic studies, involve 
electrophoretic techniques, specifically free solution isotachophoresis (Böttcher et al., 2000), 
and chromatographic techniques, such as fast protein liquid chromatography (Collins & 
Olivier, 2010; Richardson et al., 2009) and size exclusion/affinity chromatographies (Gordon 
et al., 2010). 
2.5.1 VLDL 
Both 2DE coupled to MS and gel-free MS approaches have been applied to the study of 
VLDL protein composition. Mancone et al., by using 2DE coupled to MALDI TOF/TOF MS 
analysis, provided a detailed map of VLDL, isolated by the classical ultracentrifugation 
method, from a plasma pool of 3 healthy volunteers. They identified two newly VLDL-
associated proteins, namely apo L-I and prenylcysteine lyase that were known to be 
associated with HDL, and some post-translational modifications of Apo E 
(Thr212glycosylations) and apo L-I (Ser296phosphorylation) (Mancone et al., 2007). Sun et al. 
used two different analytical approaches to compare the protein content of VLDL and LDL 
isolated from pooled samples of healthy subjects by either NaBr or iodixanol gradient 
ultracentrifugation. By using a gel-free approach based on LC coupled to MS/MS analysis 
of tryptic digests labeled with iTRAQ (isobaric tag for relative and absolute quantitation) 
tags, they revealed 15 proteins differentially expressed in the two classes of lipoproteins. By 
using 2DE coupled with LC MS/MS, they further revealed 6 proteins differentially 
expressed as well. Moreover, the 5 apo A-I isoforms were found to be phosphorylated. This 
study, besides describing the VLDL and LDL lipoproteomes, provided insights into the 
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metabolic changes, in terms of protein composition, during physiological VLDL to LDL 
transition (Sun et al., 2010). While the studies described above focused on the human 
lipoproteome of mature VLDL particles, other researches tried to shed light on VLDL 
assembly and maturation in animal models. For example, Rashid et al. immunopurified apo 
B from rat liver microsomes treated with chemical crosslinkers. Then, using LC MS/MS 
technology, they identified 99 unique proteins that co-immunoprecipitated with apo B, 
many of which were ribosomal proteins (Rashid et al., 2002). 
Bondarenko et al. applied MALDI TOF and ESI TOF MS techniques to identify low 
molecular weight proteins constituting VLDL from 3 healthy subjects and 1 hyperlipidemic 
subject without previous tryptic digestion. By this approach they identified 15 apo C 
isoforms and 1 apo E isoform and observed higher level of apo C-III in the hyperlipidemic 
subject (Bondarenko et al., 1999).  
2.5.2 LDL 
LDL particles have been studied using different proteomic approaches. Karlsson et al. 
provided a 2DE map of LDL-associated proteins from a pooled plasma of 4 healthy subjects 
purified by KBr density gradient ultracentrifugation. Their results confirmed the presence of 
proteins known to be associated with LDL particles, showing that many of these were 
present in different isoforms. In particular, they detected three proteins not previously 
identified in LDL: serum amyloid A-IV, calgranulin A, and lysozyme C. To confirm that the 
proteins identified were truly associated with LDL rather than adsorbed during the isolation 
procedure, LDL was also purified by size-exclusion chromatography (Karlsson et al., 2005a). 
Moreover, they described three isoforms of apo M that were characterized for PTMs in a 
following work (Karlsson et al., 2006). Stahlman et al. applied 2DE coupled to MALDI 
TOF/TOF and SELDI TOF MS as well, to compare VLDL, LDL and HDL isolated from 
pooled plasma of 5 healthy donors by ultracentrifugation using either KBr or D2O/sucrose 
to generate the gradient. VLDL profiles obtained with the two procedure of isolation were 
almost identical. Conversely, 2DE maps and SELDI TOF profiles of LDL and HDL were 
qualitatively similar, but differed in relative abundance of some protein species. Moreover, a 
reduced protein-lipids ratio was detected in LDL and HDL fractions purified by using KBr 
indicating that in the D2O buffer the lipoproteins retained a higher content of exchangeable 
apoproteins (Ståhlman et al., 2008). LDL-associated proteins have also been studied using 
other proteomic approaches. Banfi et al. applied liquid-phase IEF and 1DE coupled with LC 
MS/MS to characterize the proteome of LDL isolated by density gradient 
ultracentrifugation from healthy subjects. They identified LDL-associated proteins not 
previously described, including prenylcysteine lyase (PCL1), orosomucoid, retinol-binding 
protein, and paraoxonase-1. The authors analysed PCL1 distribution in all the lipoprotein 
classes isolated by ultracentrifugation from 6 healthy subjects showing a decline from VLDL 
to LDL to HDL and its absence in lipoprotein-depleted plasma. Due to the oxidizing role of 
PCL1, they hypothesized that lipoproteins can themselves generate pro-oxidant species, 
thus suggesting a new role for lipoprotein in the development of atherosclerosis (Banfi et al., 
2009). Bancells et al. analysed the proteome of LDL subfractions isolated by anion exchange 
chromatography after sequential ultracentrifugation of pooled healthy subjects plasma. 
Proteomic analysis, performed by LC MS/MS method, revealed the presence of 28 proteins 
most of which were involved in inflammation, coagulation and innate immunity, besides 
apolipoproteins involved in lipid metabolism. They observed that electronegative LDL, a 
minor subfraction of LDL fraction, has a higher content of minor proteins, especially apo F 
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and apo J, compared to electropositive LDL (Bancells et al, 2010). Collins et al. performed a 
proteomic analysis, applying LC MS/MS, to compare the lipoprotein-associated proteins 
derived from plasma and serum samples. They isolated both HDL and LDL from healthy 
subjects by means of fast protein liquid chromatography-size exclusion chromatography 
(FPLC-SEC). 16 proteins, several of which were complement subcomponents, were found 
only in the LDL fraction. 65 proteins were identified to be unique to HDL, while another list 
of proteins was found to overlap between the two lipoprotein fractions. Regarding the 
differences between plasma- and serum-derived LDL and HDL particles, the authors 
reported that the most relevant differences regarded fibrinogen proteins which were 
depleted in serum. Therefore, they stated that, apart from significantly higher levels of apo 
B-100 in LDL purified from serum samples, comparative proteomic analysis of plasma and 
serum gives similar results (Collins & Olivier, 2010).  
Up to date, only few studies on LDL proteomics and atherosclerosis have been reported. 
2DE coupled with LC MS/MS and label-free quantitative MS (LFQMS) was applied by 
Richardson et al. to the analysis of LDL in the early stages of atherosclerosis in an animal 
model. LDL was isolated by fast protein LC (FPLC) from non-diabetic hyperlipidemic, 
diabetic dyslipidemic, diabetic dyslipidemic under exercise training, and healthy Yucatan 
pigs (Richardson et al., 2009). They identified 28 unique proteins and detected several 
differential expression patterns for apo E, A-I, C-III, fibrinogen, apo B, adiponectin, alpha-2-
macroblobulin, complement C1q, ficolin, and apo J. Since LDL was isolated from pigs in the 
early stages of atherosclerosis, the alterations observed might be involved in the initiating 
stages of the disease. LDL-associated proteins have also been studied using other proteomic 
approaches. For example Davidsson et al. applied SELDI TOF technologies to compare LDL 
associated proteins from atherosclerotic patients (having either metabolic syndrome or 
diabetes) to that from healthy subjects. They focused on small dense LDL isolated by means 
of gradient ultracentrifugation using D2O. The results showed that LDL from patients had 
lower content of apo A-I, apo C-I and apo E and higher content of apo C-III, the latter 
responsible for higher affinity for arterial proteoglycans that could facilitate LDL in situ 
oxidative modifications (Davidsson et al., 2005). 
2.5.3 HDL 
HDL is the most studied among lipoprotein particles, probably because of its anti-
atherogenic functions. Proteomic studies in humans succeeded in identifying, besides the 
known apolipoproteins involved in the lipoprotein metabolism, other associated proteins 
such as acute-phase response proteins, proteinase inhibitors, and members of the 
complement activation. Therefore, characterizing the HDL proteome should help in the 
identification of novel anti-inflammatory and cardioprotective actions of HDL and could 
provide insights into lipid therapy. The most used among the several proteomic approaches 
that have been applied to characterize the HDL-associated proteins is 2DE coupled with MS. 
Böttcher et al. applied two-dimensional non-denaturing gradient gel electrophoresis (2D-
GGE) and immunoblotting to analyse HDL subfractions isolated from healthy subjects. By 
means of free solution isotachophoresis (FS-ITP), they separated 3 HDL subfractions, 
namely fast (fHDL), intermediate (iHDL) and slow-migrating (sHDL). Proteomic analysis 
showed compositional differences in HDL subfractions. In particular, they observed that 
fHDL and iHDL contained the bulk of HDL and of apo A-I. Apolipoproteins other than apo 
A-I and apo A-II were not detectable in fHDL, while sHDL contained several minor 
apolipoproteins such as apo A-IV, apo D, apo E, apo J, and factor H. Apo C-III was found 
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mainly in iHDL and sHDL with only little apo C-III in fHDL (Böttcher et al., 2000). A study 
performed by Ogorzalek Loo et al. suggests that a synergy between classical 2D gels and 
virtual 2D gels can be useful for studying HDL protein composition. Virtual 2DE is based on 
combining a first-dimensional isoelectric focusing (IEF) separation on polyacrylamide gels 
with MALDI MS surface scanning of the dried gel. In such a way, a virtual 2D gel can be 
created, generating an image in which mass spectrometry substitutes the second-dimension 
SDS-PAGE separation. By this approach the authors examined HDL isolated from human 
sera by selected-affinity immunosorption of apo A-I and revealed 42 unique masses for 
protein species with isoelectric points between pH 5.47–5.04 (Ogorzalek Loo et al., 2004). 
Heller et al. by using multiple proteomic approaches such as native or denaturing PAGE 
coupled with LC MS/MS, shotgun LC MS/MS and MALDI TOF MS profiling, analysed the 
protein complement of HDL3, HDL2, HDL2/LDL and LDL/VLDL enriched fractions, 
isolated from a plasma pool of 10,000 healthy donors by density gradient 
ultracentrifugation. Therefore, they were able to characterize comprehensively the protein 
composition of the purified lipoprotein fractions (Heller et al., 2005). Karlsson et al. 
provided a detailed 2DE map of HDL2 and HDL3 isolated by salt gradient 
ultracentrifugation from pooled plasma of 4 healthy volunteers. Besides several isoforms of 
apolipoproteins already described to associate with HDL, they identified new proteins such 
as ǂ-1-antitrypsin, two isoforms of salivary-ǂ-amylase in HDL2 and a glycosylated apoAII in 
HDL3 (Karlsson et al., 2005b). By using 1DE and 2DE MALDI TOF MS and isotope-coded 
affinity tag (ICAT), Rezaee et al. detected many more proteins than Karlsson et al. in 
ultracentrifugally isolated HDL. This was the first study employing an ICAT method to 
identify lower abundance proteins. The overall identified proteins are known to be involved 
in different functions, such as lipid transport and metabolism, inflammation, immune 
system, hemostasis and thrombosis (Rezaee et al., 2006). The higher number of identified 
proteins could be ascribed to the use of ICAT method, that improve the sensitivity of the 
detection, as well as to the use of a single step of ultracentrifugation to isolate HDL. 
Khovidhunkit et al. investigated changes in proteins associated to HDL during 
inflammation by means of 2DE and LC MS/MS in an animal model. For this purpose, they 
analysed HDL isolated by salt gradient ultracentrifugation from sera of mice injected with 
normal saline or with endotoxin so detecting increased levels of SAA, apo E, apo A-IV and 
apo A-V and decreased levels of apo A-I and apo A-II in acute-phase HDL (Khovidhunkit et 
al., 2004).  
Besides 2DE analyses, several groups have applied different gel-free proteomic approaches 
to characterize HDL proteome in healthy subjects. One of the first attempts was performed 
by Bondarenko et al. that used MALDI TOF MS and ESI TOF MS techniques to the analysis 
of intact protein of HDL isolated by density gradient ultracentrifugation in sucrose solution. 
They observed forty-nine peaks in the MALDI spectrum and 11 species in the ESI MS 
spectrum corresponding to the most abundant apolipoproteins, such as apo A-I, apo A-II, 
apo C-I, apo C-II, and apo C-III showing different isoforms due to post-translational 
modifications (Bondarenko et al., 2002). Applying immobilized pH gradient isoelectric 
focusing coupled with MALDI TOF MS, Farwig et al. were able to detect also SAA-IV in 
HDL isolated by ultracentrifugation in CsBiEDTA. They developed a successful method for 
recovering the apolipoproteins from immobilized pH gradient gels prior to MALDI 
analysis, demonstrating the analytical power of linking the IPG pI profile with MALDI TOF 
MS analysis (Farwig et al., 2003). Hortin et al. focused on HDL-associated low molecular 
weight peptides. By using HPLC and MALDI TOF MS or HPLC-ion trap mass spectrometry, 
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68 peptides in the 1-5 kDa size range were identified in ultracentrifugally isolated HDL. 
Among these, 19 were fragments derived from well-known HDL-associated protein while 
others were derived from non-lipoprotein plasma proteins as fibrinogen, ǂ1-proteinase 
inhibitor, and transthyretin, suggesting that HDL particles may represent significant 
reservoirs of small peptides in the circulation (Hortin et al., 2006). Levels et al. applied 
SELDI TOF MS technologies to HDL isolated from normolipidemic individuals by means of 
immunocapturing directly on a SELDI protein chip covalently bound with anti-apo AI or 
anti apo-AII antibodies. In this way, 95 peaks in the 3–50 kDa molecular mass range and 27 
more peaks between 50 and 160 kDa were detected (Levels et al., 2007). Gordon et al. 
applied MS-based proteomic approaches to the analysis of HDL purified from healthy 
subjects by means of gel filtration chromatography. To overcome problems related to 
nonspecific co-purification, they isolated only phospholipid-containing particles using 
calcium silicate hydrate (CSH), that were subjected to trypsin digestion while still bound to 
the CSH for identification by means of LC MS/MS. By this approach 47 proteins were 
identified. Among these, 14 were described as newly discovered HDL-associated proteins 
that support roles for HDL in complement regulation and protease inhibition (Gordon et al., 
2010). To investigate the role of specific subspecies in the anti-atherogenic effects of HDL, 
Davidson et al. applied LC MS/MS to investigate the distribution of associated proteins 
across 5 subpopulations of HDL from healthy human volunteers. Subjecting one set of 
samples to sequential ultracentrifugation followed by salt gradient ultracentrifugation, and 
the other one to a single step of salt gradient ultracentrifugation they identified 22 and 28 
proteins, respectively. Among them, the majority were apolipoproteins already known to be 
associated with ultracentrifugally-isolated HDL, while several complement factors and 
protease inhibitors already documented in other proteomic studies were not detected. By 
using peptide counts determined by MS, they monitored the relative abundance of a given 
protein across the HDL subfractions. Some proteins were found to associate preferentially to 
a specific subclass, while others were uniformly distributed across the subpopulations. This 
finding supports the proposal that HDL is composed of distinct subpopulations of particles 
that have discreet biological properties (Davidson et al., 2009).  
A limited number of studies have focused on HDL proteomes in relation to atherosclerosis. 
Vaisar et al. used a shotgun LC MS/MS approach to identify proteins associated to total 
plasma HDL isolated from 20 healthy individuals. In this way, they described 48 proteins, 
13 of which not yet known to associate to HDL. Moreover, they compared plasma HDL3 
fraction isolated from 6 healthy donors and 7 CAD patients. By means of Gene Ontology 
(GO) Consortium analysis, they were able to associate the array of HDL proteins to 
biological processes. Members of the complement pathway and endopeptidase inhibitors 
were found, suggesting that HDL plays also roles in regulating the complement system and 
protecting tissue from proteolysis. Thereafter, they found that some proteins associated to 
HDL3 were upregulated in CAD patients, in particular apo C-IV, PON1, complement C3, 
apo A-IV, and apo E. Interestingly, they found three of these proteins also in HDL isolated 
from human carotid atherosclerotic tissues, being apo E the most abundant (Vaisar et al., 
2007). In another study, they investigated whether combined statin and niacin therapy, 
which increase HDL cholesterol levels and reduce CAD risk, could reverse the changes in 
the protein composition observed in HDL3. For this purpose HDL3, isolated from 6 CAD 
patients before and 1 year after combined therapy, were subjected to LC–Fourier Transform 
Ion Cyclotron Resonance MS. By means of spectral counting and extracted ion 
chromatograms they found that treatment decreased apo E levels and increased apo J, apo F, 
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and phospholipid transfer protein levels (Green et al., 2008). In a successive study, they 
investigated if protein composition was altered in HDL2 isolated from CAD patients. 
Ultracentrifugally isolated HDL2 was digested with trypsin and analysed by MALDI TOF 
MS and pattern recognition analysis. The most significant informative features were then 
subjected to LC MALDI MS/MS for identification. This analysis revealed that HDL2 of CAD 
subjects carried a distinct protein cargo with increased levels of apo C-III and decreased 
levels of apo C-I, two apolipoproteins involved in the metabolism of HDL particles. 
Moreover, they found increased levels of apo A-I peptides containing oxidized methionine 
indicating the occurence of oxidative processes in CAD patients (Vaisar et al., 2010). Heller 
et al. used a shotgun LC MS/MS approach to characterize HDL protein composition of 7 
hypercholesterolemic subjects and 9 normolipidemic ones. They used the peptide match 
score summation index, based on probabilistic peptide scores for absolute protein 
quantitation. By this approach, they found that in hypercholesterolemic subjects apo A-I 
levels were reduced while apo C-I, apo C-III, and apo E levels were increased, suggesting 
that HDL protein composition could be altered in lipemic disease (Heller et al., 2007). Mazur 
et al. applied differential top-down mass spectrometry to compare HDL3 protein profiles 
between 3 subjects having low HDL cholesterol and 3 subjects having high HDL cholesterol. 
Differently from the so called “bottom up” proteomic methods that are based on the 
digestion of proteins into short peptides, “top-down” proteomic techniques characterize 
intact proteins. In this study HDL3 samples were analysed by a reverse-phase nano-HPLC 
coupled to a linear trap quadrupole Fourier transform (LTQ-FT) hybrid mass spectrometer. 
The authors found 380 peaks that changed significantly in protein abundance between high 
HDL-c and low HDL-c subject groups demonstrating that this approach is suitable for the 
detection of quantitative differences in proteins and protein isoforms in human HDL 
samples (Mazur et al., 2010). 
Very recently, Levels et al., applied SELDI TOF MS to HDL isolated, by apo A-I 
immunocapturing, from healthy subjects having low HDL-c and high HDL-c challenged 
with an endotoxin for 24 hours. Overall they observed profound changes in 21 markers in 
both study groups proteome irrespective of HDL cholesterol levels (Levels et al., 2011). 
Alwaili et al. applied 1D followed by LC-MS/MS to HDL isolated by sequential 
ultracentrifugation from male control, stable CAD, and ACS subjects (n=10/group). They 
identified 67 HDL-associated proteins involved in lipid binding, acute-phase response, 
immune response, and endopeptidase/protease inhibition. By means of spectral counting 
they found that nine proteins were differently abundant. Among them, apo A-IV was 
significantly reduced, whereas serum amyloid A and complement C3 were significantly 
increased in ACS patients compared to either controls or CAD subjects, as confirmed by 
western blotting and ELISA (Alwaili et al, 2011). 
Recently, our research group started to study lipoproteomic profiles in relation to 
atherosclerosis (Formato et al., 2011). For this purpose we purified plasma VLDL, LDL, and 
HDL from patients undergoing carotid endarterectomy and from healthy normolipidemic 
donors by single isopycnic salt density gradient ultracentrifugation, followed by a second 
step of ultracentrifugation. Samples were subjected to 2DE followed by PMF analysis as 
reported in figure 2. In this way, we identified 21 spots corresponding to about 96% of 52 
protein spots detected in VLDL, 22 spots corresponding to about 92% of 43 spots in LDL, 
and 20 spots corresponding to about 96% of 60 spots in HDL. The relative abundance of 
several identified lipoprotein-associated proteins differed between patients and healthy 
subjects (paper in preparation).  
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Fig. 2. Schematic workflow of the proteomic analysis of plasma lipoproteins adopted in our 
laboratory. Representative 2D maps of isolated VLDL and whole plasma are reported. 
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3. Conclusions 
Plaque rupture and thrombosis are the most important clinical complications in the 
pathogenesis of vascular diseases. To date, many efforts have been done to elucidate 
mechanisms underlying plaque vulnerability and to identify reliable specific markers of 
plaques prone to rupture. In the last years, with the improvement of proteomic tools, large-
scale technologies have been proved valuable in attempting to unravel pathways of complex 
diseases and biomarkers for early diagnosis and patients follow up. Collecting multiple 
biomarkers would be preferable over single markers in terms of higher sensitivity and 
specificity for the diagnosis of cardiovascular diseases. In this chapter, we have reviewed a 
great deal of information obtained by applying proteomics to the study of 
proteome/secretome from atherosclerotic tissues and plasma lipoproteins. In tissue 
proteomics, major drawbacks such as the plaque complexity, tissue sampling and 
availability, and the choice of the proper controls could affect the analysis. Even though 
results reported above seem to be quite promising, large-scale clinical studies are required 
to validate the usefulness of newly identified biomarkers. Moreover, there are several 
aspects of the atherosclerotic process that deserve further investigation. The analysis of laser 
captured microdissections by proteomics is still in its infancy but it could reveal valuable 
topological differences between specific areas of such a heterogeneous environment. 
Atherosclerotic plaques are characterized by the presence of an imbalance between oxidant 
and antioxidant species toward the former, leading to deep protein modifications. In this 
respect, recent advances in protein post-translational modifications analysis by mass 
spectrometry could be helpful. To date, many studies have been performed on proteome of 
purified plasma lipoproteins focusing mainly on HDL and LDL due to their association with 
atherosclerosis. As far as we know, no proteomic analyses have been performed on Lp(a). 
Since it is well known that elevated Lp(a) plasma levels are an important risk factor in 
atherogenesis, it would be of great interest to elucidate its apolipoprotein composition in 
relation to cardiovascular diseases. Another promising topic for future investigations is the 
characterization of proteomes of lipoproteins retained in atherosclerotic plaque. Finally, 
besides the great deal of work to be done in the future in both improving proteomic 
technologies and providing clues for the many aspects not yet investigated, it will also be 
necessary to put efforts on a comprehensive analysis of the huge quantity of data provided 
by the several proteomic studies. 
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